CKD Area，SC0062, a highly ETA-Selective receptor antagonist，has completed phaseⅠ trial in healthy volunteers showing favorable safety profile，no edema reported. SC0062 has the characteristics of high ETA/ETB selection ratio and has the potential make a breakthroughs in CKD ( such as IgA、DKD）.

DDR Pathway，SC0191 is the first WEE1 Kinase small molecule inhibitor IND approved by NMPA，currently in PhaseⅠdose escalation. In preclinical studies, SC0191 has shown favorable safety profile and demonstrated high antitumor activity as a single agent or in combination with other agents in a variety of animal models.

T-Cell Engager，BC3448 is a CD3xEGFR bispecific antibody that activates T cells to kill tumor cells with EGFR expression，and designed to have a stronger binding affinity for EGFR than that for CD3, which may help re-duce the risk of cytokine release syndrome (CRS）. In preclinical in vitro and in vivo studies, BC3448 demonstrated antitumor activities regardless of the mutation status of EGFR, KRAS or BRAF genes. BC3448 is in PhaseⅠdose escalation.